UCB recently announced that the US Food and Drug Administration (FDA) has approved a label extension for the company's anti-epileptic drug (AED) Vimpat (lacosamide) CV as an oral option for the treatment of partial-onset seizures (POS) in pediatric patients aged ≥4 years. UCB is headquartered in Atlanta, GA, and Brussels, Belgium.
Indications: This new approval provides clinicians with the option to prescribe Vimpat to their pediatric patients either as an oral solution or a convenient tablet, allowing for flexible administration options, an important consideration when treating children.
Dosage/administration: For pediatric patients from 4 years to <17 years, the recommended dosage is based on body weight and is administered orally twice daily. Increased dosage is based on clinical response and tolerability, and no more frequently than once per week is recommended.
Adverse reactions: Adverse reactions in pediatric patients are similar those of adult patients: diplopia, headache, dizziness, and nausea.
UCB's VIMPAT® (lacosamide) now approved by FDA to treat partial-onset seizures in pediatric epilepsy patients. [news release]. Atlanta, GA, and Brussels, Belgium: UCB. November 6, 2017. https://www.prnewswire.com/news-releases/ucbs-vimpat-lacosamide-now-approved-by-fda-to-treat-partial-onset-seizures-in-pediatric-epilepsy-patients-300549924.html. Accessed November 9, 2017.
This Week's Must Reads
Possible Link: Hepatic Steatosis and Brain Aging, JAMA Neurol; ePub 2017 Nov 20; Weinstein, et al
Neurologic Drug Shortages May Compromise Care, Neurology; ePub 2017 Nov 15; Omorodion, et al
Sleep Fragmentation Linked with PD in Older Adults, Mov Disord; ePub 2017 Oct 30; Sohail, Yu, et al
Dietary Sodium to Potassium Ratio and Stroke Risk, Stroke; ePub 2017 Oct 10; Willey, Gardener, et al
Sleep Apnea Did Not Accelerate Kidney Decline, Sleep; ePub 2017 Nov 3; Canales, Hagen, et al
Must Reads in Epilepsy & Seizures
FDA Approves Oral Option for Pediatric Epilepsy, UCB news release; 2017 Nov 6
Psychogenic, Non-Epileptic Seizure Screening Aids, Epilepsia; ePub 2017 Sep 12; Kerr, Janio, et al
FDA Approves Antiepileptic Drug for Age 4 and Older, Sunovion news release; 2017 Sep 14
Survivors of Sepsis Face Long-term Seizure Risk, Neurology; ePub 2017 Sep 6; Reznik, et al
Sudden Deaths Among Patients with Epilepsy, Neurology; ePub 2017 Aug 2; Devinsky, et al